{"id":"W2336457573","doi":"10.1200/jco.2015.33.3_suppl.9","title":"INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)—A study by the Australasian Gastrointestinal Trials Group (AGITG), first results.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre; Saint John Regional Hospital; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Regorafenib; Population; Placebo; Ramucirumab; Adverse effect; Phases of clinical research; Gastroenterology; Cancer; Progression-free survival; Refractory (planetary science); Surgery; Oncology; Chemotherapy; Clinical trial; Colorectal cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.0456914,0.0004397943,0.008225978,0.0006153358,0.00009283836,0.00002987123,0.0006005768,0.0002196441,0.0001098321],"category_scores_gemma":[0.03511903,0.0002335182,0.00116724,0.0007745723,0.0003629279,0.0002460835,0.0001702827,0.002060706,0.000002838022],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005313437,"about_ca_system_score_gemma":0.001621574,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008533328,"about_ca_topic_score_gemma":0.002621533,"domain_scores_codex":[0.9829355,0.004764885,0.0101105,0.0005023432,0.001184091,0.0005026396],"domain_scores_gemma":[0.975643,0.01315169,0.009205404,0.0005268203,0.0009212184,0.0005518918],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9189835,0.02852295,0.01619661,0.00001838071,0.001604479,0.0007619645,0.001420231,0.0002203464,0.00001599521,0.00000594739,0.01094031,0.02130926],"study_design_scores_gemma":[0.8823454,0.09528596,0.004198284,0.0001947243,0.003287145,0.0001015407,0.01049158,0.0001382697,0.000004190494,0.00002922454,0.003789775,0.0001338381],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9813771,0.0007514011,0.000119336,0.007526115,0.001620726,0.007805664,0.00001215395,0.00001739593,0.0007701496],"genre_scores_gemma":[0.9963288,0.0002984415,0.0005051663,0.0002459879,0.0009894784,0.0002381971,0.000007379104,0.00003125077,0.001355352],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06676301,"threshold_uncertainty_score":0.9826615,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2245218974730568,"score_gpt":0.5075961454477481,"score_spread":0.2830742479746913,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}